[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acs---acute-coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acs---acute-coronary-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,97,122,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100614762","european-unified-registries-for-heart-care-evaluation-and-randomised-trials-italy-100614762",false,"NCT07283809","European Unified Registries for Heart Care Evaluation and Randomised Trials Italy","European Unified Registries for Heart Care Evaluation and Randomised Trials","EuroHeart ITA","Inclusion Criteria:\n\n* Patients ≥18 years of age.\n* Males and females at birth.\n* At least one of the following clinical conditions:\n* Hospitalization for Acute Coronary Syndrome (ACS)\n* Heart failure (HF, outpatients, and\u002For inpatients)\n* Atrial fibrillation (A Fib, outpatients and\u002For inpatients)\n* Signed informed consent for the study and for privacy.\n\nExclusion Criteria:\n\n* patients who do not sign the consent to participate in the project and\u002For Privacy","ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","12 Months","OBSERVATIONAL","Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and\u002For harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.",[26],"ACS - Acute Coronary Syndrome",[28,29,30,31,32,33],"Quality indicators","ACS","STEMI","NSTEMI","ESC","Guidelines","RECRUITING","2026-01-07",{"date":37,"type":38},"2026-01-12","ACTUAL",{"date":40,"type":38},"2024-09-15",{"date":42,"type":21},"2027-12-30",{"name":44,"class":45},"Heart Care Foundation","OTHER",57,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":75,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":57,"type":21},50,"INTERVENTIONAL",[60],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[26,63,64,65,66,67,68,69,70,71,72,73,74],"Ticagrelor","Microbiota","Platelet Aggregation","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[76,77,78,79,80,81,82,83,84,85],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","NOT_YET_RECRUITING","2025-09-25",{"date":89,"type":38},"2025-10-02",{"date":91,"type":21},"2026-01-01",{"date":93,"type":21},"2027-06-30",{"name":95,"class":45},"Collegium Medicum w Bydgoszczy",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":105,"targetDuration":4,"studyType":58,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":96},"100597870","multi-omics-characterization-and-model-construction-of-colchicine-anti-inflammatory-therapy-efficacy-in-acs-patients-100597870","NCT07064109","Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients","Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in Acute Coronary Syndromes Patients","MCM-CATE-ACS","Inclusion Criteria:\n\n* Between the ages of 18 and 80\n* ACS (STEMI or NSTE-ACS)\n* Patients to receive standardised drug therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Any contraindication to colchicine or known intolerance to colchicine\n* Has been using colchicine for a prolonged period of time for other medical conditions\n* Women of childbearing age who are pregnant, breastfeeding or not using effective contraception\n* Coronary artery bypass grafting within the last 3 years or planned\n* Severe hepatic impairment: elevated serum alanine aminotransferase and\u002For aminotransferase (ALT) and\u002For aminotransferase (AST) levels of up to three times the upper limit of normal\n* Severe renal impairment: eGFR \\\u003C30mL\u002Fmin\u002F1.73m2\n* Thrombocytopenia (platelet count less than 100\\*10⁹\u002FL)\n* Active diarrhoea\n* Infectious diseases: presence of uncontrollable infectious diseases\n* Immune-related diseases: known immune diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumours, etc.\n* Strong CYP3A4 or P glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) are already in use and no alternative medications can be administered\n* Planning to use systemic anti-inflammatory therapies such as NSAIDs, hormones, immunomodulators and chemotherapeutic agents",{"count":106,"type":21},380,[108],"NA","The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are\n\n\\- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.",[26],[29,112],"colchicine","2025-09-09",{"date":115,"type":38},"2025-09-15",{"date":117,"type":38},"2025-07-01",{"date":119,"type":21},"2027-07-01",{"name":121,"class":45},"Shanghai Tongji Hospital, Tongji University School of Medicine",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":132,"conditions":133,"keywords":142,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100605065","cardiovascular-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100605065","NCT07157670","Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","ALLOCARDIOTOX","Inclusion Criteria:\n\n* Age ≥ 15 years\n* Informed about the study and without objection to participation (or with consent from legal guardians)\n* Undergoing allogeneic HSCT\n\nExclusion Criteria:\n\n* Patient not followed up at the participating center\n* Pregnant or breastfeeding women\n* Patient not affiliated with social security\n* Patient under guardianship, curatorship, or legal protection","15 Years",{"count":131,"type":21},400,"Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.\n\nIt is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.\n\nThis multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.",[134,135,136,137,26,138,139,140,141],"Cardiotoxicity","DPP3","HSCT","Allogeneic Hematopoietic Stem Cell Transplantation","Cardiac Dysfunction","Arrythmia, Cardiac","Pulmonary Hypertension","Machine Learning",[135,136,134,143,141],"Allogeneic hematopoietic stem cell transplantation","2025-09-02",{"date":146,"type":38},"2025-09-05",{"date":115,"type":21},{"date":149,"type":21},"2028-09-15",{"name":151,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":159,"targetDuration":4,"studyType":58,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":96},"100537904","phase-4-cyp2c19-genotype-guided-p2y12-receptor-inhibitor-selection-after-complex-percutaneous-coronary-intervention-100537904","NCT06283888","CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention","Safety and Efficacy of CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection Versus Conventional Antiplatelet Therapy After Complex Percutaneous Coronary Intervention: The PRECISE-PCI Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinical Criteria:\n\n   * Patients aged between 18-80 years old.\n   * Patients with ACS (UA\u002FNSTEMI\u002FSTEMI) undergoing PCI.\n   * Patients will be treated with DAPT (P2Y12 inhibitors+aspirin) for at least 3 months.\n   * Patients are willing to provide a DNA sample (via blood draw) for CYP2C19 genotyping.\n   * Patients provide written informed consent before enrollment.\n2. Angiographic Criteria (meet at least 1 of the following characteristics):\n\n   * Thrombotic target lesion.\n   * Calcified target lesion requiring rotational atherectomy or intravascular lithotripsy\n   * Multivessel (≥2 vessels) disease will be treated.\n   * Multi-target lesions (≥3 lesions) will be treated.\n   * Multi-stent (≥3 stents) will be implanted.\n   * Total stent length≥60 mm.\n   * Bifurcation lesion requiring at least 2 stents.\n   * PCI for left main.\n   * PCI for chronic total occlusion.\n   * PCI for bypass graft.\n\nExclusion Criteria:\n\n* Patient with known CYP2C19 genotype before randomization.\n* Anticipated discontinuation of clopidogrel or ticagrelor within the 12-month follow-up period.\n* Planned surgery within 90 days.\n* Requiring oral anticoagulation therapy (eg, atrial fibrillation, deep vein thrombosis, pulmonary thromboembolism)\n* Intracranial\u002Fgastrointestinal\u002Furogenital bleeding within 6 months.\n* Active bleeding or bleeding diathesis, thrombocytopenia (platelet \\\u003C100,000\u002FmL) or hemoglobin \\\u003C10 g\u002FdL\n* Hepatic dysfunction (serum liver enzyme\\>3 times the normal limit)\n* Renal failure (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2 or requiring dialysis)\n* Concomitant therapy with a strong CYP3A4 inhibitor or inducer\n* Life expectancy \\\u003C 1 year",{"count":160,"type":21},1200,[60],"In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood \"East Asian Paradox\", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice.",[26,164],"CYP2C19 Polymorphism",[166,167,168],"CYP2C19 Genotype","P2Y12 Receptor Inhibitor","Complex PCI","2024-03-18",{"date":171,"type":38},"2024-03-20",{"date":173,"type":21},"2024-04-01",{"date":175,"type":21},"2028-12-01",{"name":177,"class":45},"Zunyi Medical College"]